NCT00812266

Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)

Randomized Phase III Trial of Topotecan and Cisplatin Versus Etoposide and Carboplatin in the Treatment of Patients With Previously Untreated Small Cell Lung Cancer and Extensive Disease

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 281 (actual)
• Sponsor: Danish Oncological Lung Cancer Group · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Randomised trial comparing standard chemotherapy with carboplatin and etoposide with a combination of topotecan and cisplatin in patients with inoperable lung cancer of small cell type.

Detailed description

Fase III, multicenter randomised trial comparing up to six cycles of carboplatin and etoposide with up to six cycles of topotecan and cisplatin in patients with extensive stage small cell lung cancer and PS 0-3

Conditions

• Extensive Disease
• First-Line
• Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	topotecan + cisplatin	topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W
DRUG	Etoposide + carboplatin	Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W

Timeline

• Start date: 2006-01-01
• Primary completion: 2013-12-01
• Completion: 2015-01-01
• First posted: 2008-12-22
• Last updated: 2016-01-26

Locations

1 site across 1 country: Denmark